A recent study found that continued therapy with a combination regimen until disease progression improves outcomes in patients with newly diagnosed multiple myeloma who are not eligible for ASCT.
Positron emission tomography-based molecular imaging biomarkers may predict therapeutic response and survival in patients with metastatic castration-resistant prostate cancer, researchers say.
Survival among men with de novo metastatic prostate cancer has improved since the introduction of several systemic agents for the treatment of castrate-resistant disease.
An investigation into a handful of high-quality, low-spending oncology practice sites offered insight into five specific attributes of high-value cancer care.
Investigating genetic variations within a primary tumor and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma.
A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma.
Risk algorithms for pediatric patients with acute lymphoblastic leukemia should incorporate genetics with minimal residual disease for optimal accuracy.
A recent analysis showed that aftercare strategies for soft-tissue sarcoma are misguided and are in need of time- and risk-adapted methods.
Factors predicting HER2 discordance between primary tumor and circulating tumor cells may be used as a surrogate for tumor biology and tumor heterogeneity in patients with breast cancer.
The FDA has approved an adjuvant treatment for adult patients who are at a high risk of renal cell carcinoma returning after nephrectomy.